ASTCT expert-panel guideline on acute GVHD after allogeneic transplant: MAGIC grading endorsed; biomarkers can aid risk stratification; corticosteroids remain first-line, ruxolitinib second-line (remestemcel-L an alternative in children); no consensus third-line.
Guideline
DeFilipp et al. Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines